For every argument that construes AI as essential, promising and transforming across nearly all industries, there are voiced concerns about this technology. Many people do not trust AI, claiming that intelligent machines will one day dominate humankind. But while this is a remote possibility, the harm that can be done to people (albeit mostly unintentionally) by deep learning algorithms is very tangible – and has already been known to occur in the real world.

After receiving her bachelor's degree in Biochemistry and a master's degree in Health Sciences from the University of Minho, which introduced her to the field of immunology, Cardoso embarked upon a PhD in the laboratory of Henrique Veiga-Fernandes at the Champalimaud Foundation to study the role of neuro-immune interactions in metabolism.

Everything around a malignant tumour and its metastases, from its so-called microenvironment to the patients themselves as individuals, influences cancerous growth, and ultimately the outcome of the disease. This is the take-away message from CRSy2022 – the three-day international scientific symposium that took place at the Champalimaud Foundation, in Lisbon, from 19 to 21 October.

Helena Gouveia, oncologist at the Breast Unit of the Champalimaud Foundation (CF) tells us about two important examples of collaborative endeavours between this Unit and CF’s research labs. Scientists and clinicians join efforts to do translational research/medicine – that is, to take recent scientific advances “to the patients’ bedside” as safely, quickly and efficiently as possible.

In this short video, Marcio Debiasi, oncologist at the Breast Unit of the Champalimaud Foundation, presents a study dubbed KeyPARTNER, which is being carried out in this Unit with support from industrial funders. The study’s aim is to optimize the use of chemotherapy together with immunotherapy for the treatment of so-called “triple negative” breast cancers, which are considered to be the most aggressive breast tumours.

Zoom-In on Champalimaud: Ana Beatriz Machado

Leonor Matos, Medical Oncologist at the Champalimaud Foundation’s Breast Unit, presents here the NEOPROGRAM, a project that will soon be launched in the unit, which was designed for patients who are going to receive chemotherapy or hormone therapy with curative intent. Its goal is to evaluate the benefits of different types of physical exercise for the patients’ quality of life and for tumour responses to the treatments.

This public event, organised by the RAISE (Researchers in Action for Inclusion in Science and Education) consortium composed of the NGO Native Scientist, the Champalimaud Foundation and the Instituto de Medicina Molecular João Lobo Antunes (iMM), joined the 49 ERNs that took place in 25 European countries on the same date.